Advertisement
Advertisement

MIRM

MIRM logo

Mirum Pharmaceuticals, Inc. Common Stock

121.54
USD
Sponsored
-6.16
-4.82%
Jul 10, 14:35 UTC -4
Open

MIRM Earnings Reports

Positive Surprise Ratio

MIRM beat 13 of 28 last estimates.

46%

Next Report

Date of Next Report
Jul 30, 2026
Estimate for Q2 26 (Revenue/ EPS)
$169.44M
/
-$0.69
Implied change from Q1 26 (Revenue/ EPS)
+5.98%
/
-36.11%
Implied change from Q2 25 (Revenue/ EPS)
+32.60%
/
+475.00%

Mirum Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On May 06, 2026, MIRM reported earnings of -1.08 USD per share (EPS) for Q1 26, missing the estimate of -0.36 USD, resulting in a -199.67% surprise. Revenue reached 159.88 million, compared to an expected 151.76 million, with a 5.35% difference. The market reacted with a -6.50% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of -0.69 USD, with revenue projected to reach 169.44 million USD, implying an decrease of -36.11% EPS, and increase of 5.98% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Replimune Group, Inc.
Report Date
Jun 29, 2026 For Q4 26
Estimate
-$0.72
Actual
-$0.76
Surprise
-4.52%
logo
Beyond Air, Inc. Common Stock
Report Date
Jun 26, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.63
Surprise
-9.00%
FAQ
For Q1 2026, Mirum Pharmaceuticals, Inc. Common Stock reported EPS of -$1.08, missing estimates by -199.67%, and revenue of $159.88M, 5.35% above expectations.
The stock price moved down -6.5%, changed from $110.08 before the earnings release to $102.93 the day after.
The next earning report is scheduled for Jul 30, 2026.
Based on 10 analysts, Mirum Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.69 and revenue of $169.44M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement